Loading company…
Proniras develops drugs for neurological conditions, including seizures and brain injury.
Founded in 2017 in Washington, Proniras develops drugs for neurological conditions. Its AMPA and kainate receptor antagonist is being developed for seizures and brain injury, including status epilepticus and pediatric epilepsy. The company received a USD 12.3 million grant in September 2020 from the National Institute on Drug Abuse and Johnson & Johnson Innovation, with participation from other investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in